Short Communication

Cognitive Screening for Mild Cognitive Impairment: Clinician Perspectives on Current Practices and Future Directions

Catherine Diaz-Asper[a,*], Chelsea Chandler[b] and Brita Elvevåg[c]
[a]*Department of Psychology & Center for Optimal Aging, Marymount University, Arlington, VA, USA*
[b]*Institute of Cognitive Science, University of Colorado, Boulder, CO, USA*
[c]*Department of Clinical Medicine, University of Tromsø-the Arctic University of Norway, Tromsø, Norway*

Abstract. This study surveyed 51 specialist clinicians for their views on existing cognitive screening tests for mild cognitive impairment and their opinions about a hypothetical remote screener driven by artificial intelligence (AI). Responses revealed significant concerns regarding the sensitivity, specificity, and time taken to administer current tests, along with a general willingness to consider adopting telephone-based screening driven by AI. Findings highlight the need to design screeners that address the challenges of recognizing the earliest stages of cognitive decline and that prioritize not only accuracy but also stakeholder input.

Keywords: Alzheimer's disease, artificial intelligence, attitude of health personnel, mental status and dementia test, mild cognitive impairment

INTRODUCTION

Correctly recognizing the earliest stages of cognitive decline associated with Alzheimer's disease and related dementias (ADRD) is crucial to maximize life quality and treatment options and to reduce costs associated with disability and dependency [1, 2]. However, the identification of reliable signs of ADRD at the preclinical stage can be challenging, especially for clinicians lacking specialist training [3, 4], with the result that many older adults with memory concerns fail to receive an expert evaluation and diagnosis until the disease has progressed markedly [5, 6]. A comprehensive cognitive evaluation typically requires a lengthy in-person clinical examination by a psychologist or other trained professional, which can be onerous in terms of access, time, and cost. Numerous brief paper-and-pencil screening tests for dementia are available, and typically are used in healthcare settings to identify people who would benefit from a full diagnostic workup by a specialist clinician [7]. These tests are also employed to identify participants for inclusion in clinical trials [8, 9]. However, cognitive screening tests tend to vary in their sensitivity to the earliest stages of decline [10] and are not universally offered in primary care settings [11], where concerned older adults typically first

*Correspondence to: Catherine Diaz-Asper, Marymount University, 2807 N. Glebe Rd, Arlington, VA 22207, USA. E-mail: cdiazasp@marymount.edu.

present [5]. Hence, new methods for detecting early-stage cognitive decline are needed, and some of the most promising capitalize on the rapidly advancing field of artificial intelligence (AI).

The role of artificial intelligence in cognitive screening

The development and application of AI-driven technologies in healthcare has grown exponentially in recent years, and AI-driven tools to identify cognitive decline are being applied across various modalities, including neuroimaging, genetics, blood biomarkers, and speech and language [12–15], highlighting the potential for these methods to be used in clinical settings for the detection of early cognitive decline, also known as mild cognitive impairment (MCI). Many AI-based solutions offer clinical decision support to aid in diagnosis, and tout benefits such as improved efficiency, accuracy, error detection, and cost effectiveness. This, in turn, can lead to improved productivity and profit margins at the organizational level [16].

Our own work utilizing AI to analyze speech recorded over the telephone has demonstrated success in discriminating between cognitively healthy older adults, those with MCI, and those with mild Alzheimer's disease, is rated as enjoyable and engaging by patients, and presents output to clinicians in a user-friendly dashboard interface [13, 17, 18]. An additional benefit of this approach is that it can be administered remotely, with the only technical requirement being that the patient have access to a telephone. However, it is currently unknown whether AI-driven early detection tools will appreciably improve patient outcomes [19].

Several studies have reported on physicians' attitudes towards AI in healthcare [20–23], with those in favor citing benefits such as improved patient access to screening, improved physician confidence in diagnosis, and reduced specialist time spent on tedious tasks [22]. Despite this optimism, uptake has so far generally been low [24–27], with perceived transparency and trustworthiness emerging as key concerns. This may be due to the "*black box*" nature of AI, where the process underlying the system's operation and decision-making is unknown [28]. Given the expected growth of AI-based clinical decision support tools across almost all healthcare specialties, user feedback (including both clinicians and patients) regarding acceptability will be crucial to ensure the technology's adoption and realization of potential benefits. In addition to overcoming clinician reluctance to adopt, any new AI-driven options for cognitive screening would presumably need to demonstrate clear advantages over currently available paper-and-pencil screeners. Two of the most widely-used cognitive screening tools are the Mini-Mental State Exam (MMSE) [29], and the Montreal Cognitive Assessment (MoCA) [30], both of which are brief and easy to administer. However, previous reports of both primary care and specialist clinician attitudes towards cognitive screeners cited several drawbacks, including concerns about cost and time to complete testing, and a lack of specificity in detecting MCI [6, 31, 32]. Hence, any new AI-based screeners would need to be as, or more, accurate than current tools, cost effective, and brief.

With new AI-based screening approaches on the horizon, the opinions of specialist clinicians regarding current screening practices are an important consideration for potential uptake of these tools. The current study is novel in that it surveys a group of clinicians specializing in dementia assessment for their views on currently available cognitive screening tools, and their reactions to a hypothetical AI-driven screening service delivered via the telephone. Dementia specialists were selected under the assumption that they have the most detailed knowledge and experience of cognitive decline and would be in the best position to advise on how screening tests could be improved to increase early detection. Ultimately, specialist clinician-primary care provider collaboration will be needed to evaluate new and evolving technologies in screening and diagnosis to address the significant issue of underdiagnosis at the primary care level [33].

MATERIALS AND METHODS

A 19-question survey was created using Google Forms, with questions pertaining to the professional settings of respondents, their opinions on current cognitive screening tools, how they might be improved, and questions about uptake decisions for a hypothetical AI telephone-based screening service (see Supplementary Material). The survey questions were developed by the first author based on a literature review of provider opinions about cognitive screening. Two of the AI-specific questions were taken from a study examining primary care provider opinions on uptake of a telephone screening service for cognitive decline [34]. Responses to the AI-specific questions

were measured on a 5-point Likert-type scale whereas the remaining questions required multiple choice or open-ended responses.

A convenience sample of U.S. clinicians specializing in dementia diagnosis were identified from two sources: the Alzheimer's Association and the American Association of Retired Persons' *Community Resource Finder* (https://www.communityresourcefinder.org/), and the Gerontological Society of America's *GSA Connect* (https://connect.geron.org/home). The survey link was emailed to 229 clinicians over a 9-month period in 2023 and posted on *GSA Connect* in November 2023. (Email invitations had also been sent in 2020–2021 to 13 clinicians identified from the *Community Resource Finder*).

Fifty-two responses were recorded (response rate ∼21.5%), although one was dropped from analyses because the respondent indicated that they did not work in a clinical capacity, resulting in a sample size of 51. Responses were anonymous, although respondents were eligible to receive a $10 Amazon gift card by providing their email address, which was later deleted. This study was approved by the Marymount University IRB #460. Data analysis, including descriptive statistics and chi-square analyses were conducted using SPSS version 27, with $p < 0.05$.

RESULTS

Characterizing the sample

As shown in Table 1, the majority of respondents had medical degrees and/or PhDs and specialized in gerontology, (neuro)psychology, or neurology. Most respondents worked in group settings of 20 or fewer colleagues, in university-affiliated medical centers. The majority of respondents evaluated more than 10 older adult patients a week, with nearly half spending more than 50% of their time conducting dementia evaluations.

Opinions on current cognitive screeners for MCI

The most notable concerns with current screening tools for MCI pertained to sensitivity and specificity of the instruments (52.8%) and the time-consuming nature of testing (32.2%) (see Fig. 1). The most commonly cited suggestions for how this could be improved were faster and/or shorter screening tests (24.2%) (see Fig. 2).

Table 1
Characteristics of the study sample (N=51)

	N	%
Terminal degree		
MD	25	49.0
PhD	12	23.5
MD/PhD	2	3.9
DO	3	5.9
LCSW	2	3.9
Other (misc.)	7	13.7
Specialty		
Gerontology	18	35.3
Neurology	8	15.7
Internal Medicine	2	3.9
(Neuro)psychology	12	23.5
Psychiatry	4	7.8
Other (misc.)	6	11.8
Work setting		
Hospital (outpatient clinic)	8	15.7
University-affiliated medical center	31	60.8
Private office	12	23.5
Practice		
Group	38	74.5
Individual	13	25.5
Number of practice colleagues		
1–10	28	54.9
11–20	11	21.6
21–50	3	5.9
>50	3	5.9
unknown	6	11.8
Number of adult patients 65 or older seen per week:		
1–5	4	7.8
6–10	14	27.5
11–20	14	27.5
21–30	7	13.7
>30	10	19.6
Unknown	2	3.9
Percentage of older adult patients presenting with memory concerns		
<10%	1	2.0
10–25%	9	17.6
26–50%	9	17.6
51–75%	12	23.5
>75%	20	39.2
Percentage of time spent on dementia evaluations		
<10%	6	11.8
10–25%	9	17.6
26–50%	13	25.5
51–75%	11	21.6
>75%	12	23.5

Opinions on an (hypothetical) AI-driven telephone screening service

The majority of respondents (78.4%) either agreed or strongly agreed that they would make use of a telephone-based service that could identify MCI. A one-sample chi-square goodness of fit test confirmed that the distribution of all the three types

Fig. 1. Percentage of total responses citing problems with current cognitive screeners for the identification of MCI. (Respondents could indicate more than one option).

Time consuming (32.2%)

Lack of sensitivity (26.4%)

Lack of specificity (26.4%)

Issues with repeated testing (13.8%)

Not well tolerated by patients (11.5%)

Outdated norms (2.3%)

Inadequate primary care screening (4.6%)

Delay in full workup for diagnosis (2.3%)

None (3.4%)

Fig. 2. Percentage of total responses citing how current cognitive screeners for the identification of MCI could be improved. (Respondents could indicate more than one option).

Faster/shorter tests (24.2%)

Alternate test forms (15.2%)

Better normative data (6.1%)

Primary care provider education on early screening (15.2%)

Greater insurance reimbursement (9.1%)

More sensitive tests (12.1%)

Greater face validity (12.1%)

Labs, biomarkers, other methods (6.1%)

of responses (agree, neutral, disagree) were significantly skewed towards positive opinions ($\chi^2 = 46.71$, 2 df, $p < 0.001$). Opinions on whether *patients* would make use of a telephone screener were less positively skewed (agree = 50.0%; neutral = 22%; disagree = 28%), but nonetheless still significant ($\chi^2 = 6.52$, 2 df, $p = 0.038$).

Cost was noted as a significant potential barrier to the implementation of a telephone service to identify MCI, with over half (52.9%) of respondents stat-

ing that this would influence their decision to adopt ($\chi^2 = 10.71$, 2 df, $p = 0.005$).

The most important characteristics of any proposed telephone service to screen for MCI were identified by respondents as patient tolerability (92.2%), reliability (90.2%), sensitivity (86.2%), and specificity (80.4%), with no significant differences in the proportions of agree/neutral/disagree responses by characteristic ($\chi^2 = 0.47$, 3 df, $p = 0.925$). Respondents provided a variety of preferred options when asked to name standard screeners that would be useful to present side-by-side with speech-based data for comparison purposes, citing the MoCA (38.6%) and MMSE (22.8%) most often. Other preferred screeners noted were the Mini-Cog [35] at 14.9% and ADAS-Cog [36] at 8.8%.

DISCUSSION

Recent evidence suggests that MCI is woefully underdiagnosed in primary care settings [33], arguing not only for improved education and training of primary care providers, but also for the deployment of accurate, rapid, and well tolerated screening tools. The current study surveyed clinicians specializing in the diagnosis of cognitive decline and dementia for their opinions on the current state of cognitive screening for MCI, and they cited several significant concerns. Consistent with previous reports, these concerns primarily revolved around the lack of sensitivity and specificity of the tools and the time it takes to administer, score, and interpret them [31, 32]. While commonly used tests like the MoCA and MMSE are relatively brief, the time taken to administer and score them is not inconsequential when medical appointments can be as short as 15 minutes [37]. Additionally, the MMSE's lack of sensitivity to the earliest stages of decline is well documented [38, 39], rendering it a poor choice for MCI detection. Several other options are available, yet providers may be unsure of the "best" tests to use and when/how often to use them (e.g., to avoid practice effects with repeated administration).

Respondents' most cited recommendation for the development of future cognitive screeners was to ensure they be brief, presumably due to the time constraints noted above [11, 40]. The advantage of AI-based screeners, such as those using spoken language, is that they can quantify cognitive decline using only short samples of speech (in the 1–2 minute range). The AI computations themselves can occur almost instantaneously, providing an output in real time. Our work, and that of others, has shown that this approach can accurately differentiate MCI from both healthy aging and Alzheimer's disease [13, 17, 41, 42], is rapid, and well tolerated by patients [18]. Results of the current study suggest that clinicians are also receptive to adopting a hypothetical AI telephone-based screening service such as this, deeming sensitivity, specificity, reliability and tolerability as especially important characteristics of any new tool. Our research in developing a dashboard-type output to aid clinicians in the interpretation of an individual's results suggests that both specialist clinicians and primary care providers alike could adopt the technology with little additional training required [17]. The current findings suggest that side-by-side comparisons with commonly used screeners such as the MoCA and MMSE would be a valuable addition to this dashboard.

Several limitations should be noted in this study, with the potential for response bias being the most important. A response rate of only 21.5% means that the majority of specialist clinicians who were emailed the survey link did not respond, notably limiting the study's external validity. While low, a response rate such as this is not uncommon from healthcare providers [43, 44] and several studies have proposed methods to increase survey participation in this population [45, 46]. A second limitation is that the questions regarding the hypothetical AI-driven telephone screener were vaguely worded, such that respondents may each have envisaged quite different versions of said tool, and this in turn may have influenced results. For example, we never stated specifics such as whether the service would be fully automated versus having human interaction, which tasks would be used to elicit speech samples, and how the speech samples would be recorded, transmitted and analyzed. Whether and how any of these elements were considered by respondents is unknown. Hence, a more detailed and realistic depiction of an AI telephone screening tool will be an integral component of future work. Documented clinician concerns over data privacy [22], coupled with the sheer number of AI-driven tools already available, most with limited transparency, means that patient autonomy and privacy should be central ethical concerns for any clinician considering their use.

While respondents in the current study largely agreed that their older patients would use a telephone-based screening service, there was a notable minority (28%) who did not think that they would, for rea-

sons we did not investigate. It is possible, at least in part, that individual interpretations of what this "service" would entail resulted in a variety of both positive and negative responses. The telephone is ubiquitous in most people's homes and allows for the remote administration of screening tests, but may not be appropriate for patients with hearing, speech, or severe cognitive deficits. Tolerability of fully automated tools may also be an issue for some older adults who would prefer the opportunity to interact with a human [47].

Study limitations notwithstanding, these findings provide valuable insights on the current state of cognitive screening for MCI from experts using these tools on a daily basis. The proliferation of AI-driven healthcare technologies presents a great opportunity to address the shortcomings of common cognitive screeners through the intelligent design of accurate, brief, and well tolerated tools in future.

AUTHOR CONTRIBUTIONS

Catherine Diaz-Asper (Conceptualization; Data curation; Formal analysis; Funding acquisition; Investigation; Methodology; Visualization; Writing – original draft; Writing – review & editing); Chelsea Chandler, PhD (Conceptualization; Writing – review & editing); Brita Elvevåg (Conceptualization; Writing – review & editing).

ACKNOWLEDGMENTS

The authors have no acknowledgments to report.

FUNDING

CONFLICT OF INTEREST

The authors have no conflict of interest to report.

DATA AVAILABILITY

The data supporting the findings of this study are available on request from the corresponding author. The data are not publicly available due to ethical restrictions.

SUPPLEMENTARY MATERIAL

The supplementary material is available in the electronic version of this article: https://dx.doi.org/10.3233/JAD-240293.

REFERENCES

[1]   Rasmussen J, Langerman H (2019) Alzheimer's disease – Why we need early diagnosis. *Degener Neurol Neuromuscul Dis* **9**, 123-130.

[2]   Kumar R, Lund E, Ornstein K, Li J, Covinski KE, Kelley AS (2023) Health care utilization and costs in the years preceding dementia identification. *Alzheimers Dement* **19**, 5852-5859.

[3]   Abdelnour C, Agosta F, Bozzali M, Fougère B, Iwata A, Ramin N, Takada LT, Viñuela F, Traber M (2022) Perspectives and challenges in patient stratification in Alzheimer's disease. *Alzheimers Res Ther* **14**, 112.

[4]   Porsteinsson AP, Isaacson RS, Knox S, Sabbagh MN, Rubino I (2021) Diagnosis of early Alzheimer's disease: Clinical practice in 2021. *J Prev Alzheimers Dis* **8**, 371-386.

[5]   Livingston G, Sommerlad A, Orgeta V, Costafreda SG, Huntley J, Ames D, Ballard C, Banerjee S, Burns A, Cohen-Mansfield J, Cooper C, Fox N, Gitlin LN, Howard R, Kales HC, Larson EB, Ritchie K, Rockwood K, Sampson EL, Samus Q, Schneider LS, Selbæk G, Teri L, Mukadam N (2017) Dementia prevention, intervention, and care. *Lancet* **390**, 2673-2734.

[6]   Liss JL, Seleri Assunção S, Cummings J, Atri A, Geldmacher DS, Candela SF, Devanand DP, Fillit HM, Susman J, Mintzer J, Bittner T, Brunton SA, Kerwin DR, Jackson WC, Small GW, Grossberg GT, Clevenger CK, Cotter V, Stefanacci R, Wise-Brown A, Sabbagh MN (2021) Practical recommendations for timely, accurate diagnosis of symptomatic Alzheimer's disease (MCI and dementia) in primary care: A review and synthesis. *J Intern Med* **290,** 310-334.

[7]   Levy B, Tsoy E, Gable S (2016) Developing cognitive markers of Alzheimer's disease for primary care: Implications for behavioral and global prevention. *J Alzheimers Dis* **54**, 1259-1272.

[8]   Chapman KR, Bing-Canar H, Alosco ML, Steinberg EG, Martin B, Chaisson C, Kowall N, Tripodis Y, Stern RA (2016) Mini Mental State Examination and Logical Memory scores for entry into Alzheimer's disease trials. *Alzheimers Res Ther* **8**, 9.

[9]   Goldman D, Malzbender K, Lavin-Mena L, Hughes L, Bose N, Patel D (2020) Key barriers to clinical trials for Alzheimer's disease. https://healthpolicy.usc.edu/research/key-barriers-for-clinical-trials-for-alzheimers-disease/, Last updated Aug 17, 2020, Accessed on Mar 1, 2024.

[10] De Roeck EE, De Deyn PP, Dierckx E, Engelborghs S (2019) Brief cognitive screening instruments for early detection of Alzheimer's disease: A systematic review. *Alzheimers Res Ther* **11**, 21.

[11] Sabbagh MN, Boada M, Borson S, Chilukuri M, Dubois B, Ingram J, Iwata A, Porsteinsson AP, Possin KL, Rabinovici GD, Vellas B, Chao S, Vergallo A, Hampel H (2020) Early detection of mild cognitive impairment (MCI) in primary care. *J Prev Alzheimers Dis* **7**, 165-170.

[12] Dashwood M, Churchhouse G, Young M, Kuruvilla T, (2021) Artificial intelligence as an aid to diagnosing dementia: An overview. *Prog Neurol Psychiatry* **25**, 42-47.

[13] Diaz-Asper C, Chandler C, Turner RS, Reynolds B, Elvevåg B (2022) Increasing access to cognitive screening in the elderly: Applying natural language processing methods to speech collected over the telephone. *Cortex* **156**, 26-38.

[14] Li R, Wang X, Lawler K, Garg S, Bai Q, Alty J (2022) Applications of artificial intelligence to aid early detection of dementia: A scoping review on current capabilities and future directions. *J Biomed Inform* **127**, 104030.

[15] Tsoi KKF, Jia P, Dowling NM, Titiner JR, Wagner M, Capuano AW, Donohue MC (2023) Applications of artificial intelligence in dementia research. *Camb Prism Precis Med* **1**, e9.

[16] Bygrave L (2022) Machine learning, cognitive sovereignty and data protection rights with respect to automated decisions. In *Cambridge Handbook of Information Technology, Life Sciences and Human Rights,* Ienca M, Pollicino O, Liguori L, Stefanini E, Andorno R, eds. Cambridge University Press, Cambridge, pp. 166-188.

[17] Chandler C, Diaz-Asper C, Turner RS, Reynolds B, Elvevåg B (2023) An explainable machine learning model of cognitive decline derived from speech. *Alzheimers Dement* **15**, e12516.

[18] Diaz-Asper C, Chandler C, Turner RS, Reynolds B, Elvevåg, B (2021) Acceptability of collecting speech samples from the elderly via the telephone. *Digit Health* **7**, 20552076211002103.

[19] Mohamed A, Marques O (2023) Diagnostic efficacy and clinical relevance of artificial intelligence in detecting cognitive decline. *Cureus* **15**, e47004.

[20] Al-Medfa MK, Al-Ansari AMS, Darwish AH, Qreeballa TA, Jahrami H (2023) Physicians' attitudes and knowledge toward artificial intelligence in medicine: Benefits and drawbacks. *Heliyon* **9**, e14744.

[21] Buck C, Doctor E, Hennrich J, Jöhnk J, Eymann T (2022) General practitioners' attitudes toward artificial intelligence–enabled systems: Interview study. *J Med Internet Res* **24**, e28916.

[22] Scheetz J, Rothschild P, McGuinness M, Hadoux X, Soyer HP, Janda M, Condon JJJ, Oakden-Rayner L, Palmer LJ, Keel S, van Wijngaarden P (2021) A survey of clinicians on the use of artificial intelligence in ophthalmology, dermatology, radiology and radiation oncology. *Sci Rep* **11**, 5193.

[23] Scott IA, Carter SM, Coiera E (2021) Exploring stakeholder attitudes towards AI in clinical practice. *BMJ Health Care Inform* **28**, e100450.

[24] Antoniadi AM, Du Y, Guendouz Y, Wei L, Mazo C, Becker BA, Mooney C (2021) Current challenges and future opportunities for XAI in machine learning-based clinical decision support systems: A systematic review. *Appl Sci* **11**, 5088.

[25] Higgins O, Short B, Chalup S, Wilson R (2023) Artificial intelligence (AI) and machine learning (ML) based decision support systems in mental health: An integrative review. *Int J Ment Health Nurs* **32**, 966-978.

[26] Jones C, Thornton J, Wyatt J (2023) Artificial intelligence and clinical decision support: Clinicians' perspectives on trust, trustworthiness, and liability. *Med Law Rev* **31**, 501-520.

[27] Wang D, Wang L, Zhang Z, Wang D, Zhu H, Gao Y, Fan X, Tian F (2021) "Brilliant AI doctor" in rural clinics: Challenges in AI-powered clinical decision support system deployment. In *Proceedings of the 2021 CHI conference on human factors in computing systems*, pp 1-18.

[28] Diaz-Asper C, Hauglid MK, Chandler C, Cohen AS, Foltz PW, Elvevåg B (2024) A framework for language technologies in behavioral research and clinical applications: Ethical challenges, implications and solutions. *Am Psychol* **79**, 79-91.

[29] Folstein M, Folstein S, McHugh P (1975) "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. *J Psychiatr Res* **12**, 189-198.

[30] Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H (2005) The Montreal Cognitive Assessment, MoCA: A brief screening tool for mild cognitive impairment. *J Am Geriatr Soc* **53**, 695-699.

[31] Judge D, Roberts J, Khandker RK, Ambegaonkar B, Black CM (2019) Physician practice patterns associated with diagnostic evaluation of patients with suspected mild cognitive impairment and Alzheimer's disease. *Int J Alzheimers Dis* **2019**, 4942562.

[32] Martin S, Kelly S, Khan A, Cullum S, Dening T, Rait G, Fox C, Katona C, Cosco T, Brayne C, Lafortune L (2015) Attitudes and preferences towards screening for dementia: A systematic review of the literature. *BMC Geriat* **15**, 66.

[33] Liu Y, Jun H, Becker A, Wallick C, Mattke S (2023) Detection rates of Mild Cognitive Impairment in primary care for the United States Medicare population. *J Prev Alzheimers Dis* **11**, 7-12

[34] Vaskinn A, Wilsgård I, Holm A, Wootton R, Elvevåg B (2013) A feasibility study of a telephone-based screening service for mild cognitive impairment and its uptake by elderly people. *J Telemed Telecare* **19**, 5-10.

[35] Borson S, Scanlan JM, Chen P, Ganguli M (2003) The Mini-Cog as a screen for dementia: Validation in a population-based sample. *J Am Geriatr Soc* **51**, 1451-1454.

[36] Connor DJ, Sabbagh MN (2008) Administration and scoring variance on the ADAS-Cog. *J Alzheimers Dis* **15**, 461-464.

[37] Swanson K, Matulis III J, McCoy R (2022) Association between primary care appointment lengths and subsequent ambulatory reassessment, emergency department care, and hospitalization: A cohort study. *BMC Primary Care* **23**, 39.

[38] Breton A, Casey D, Arnaoutoglou N (2019) Cognitive tests for the detection of mild cognitive impairment (MCI), the prodromal stage of dementia: Meta-analysis of diagnostic accuracy studies. *Int J Geriatr Psychiatr* **34**, 233-242.

[39] Pinto TCC, Machado L, Bulgacov TM, Rodrigues-Júnior AL, Costa MLG, Ximenes RCC, Sougey EB (2019) Is the Montreal Cognitive Assessment (MoCA) screening superior to the Mini-Mental State Examination (MMSE) in the detection of mild cognitive impairment (MCI) and Alzheimer's Disease (AD) in the elderly? *Int Psychogeriatr* **31**, 491-504.

[40] Mansfield E, Noble N, Sanson-Fisher R, Mazza D, Bryant J (2019) Primary care physicians' perceived barriers to optimal dementia care: A systematic review. *Gerontologist* **59**, e697-e708.

[41] Pulido ML, Hernández JB, Ballester MÁ, González CM, Mekyska J, Smékal Z (2020) Alzheimer's disease and automatic speech analysis: A review. *Expert Syst Appl* **150**, 113213.

[42] Shi M, Cheung G, Shahamiri S (2023) Speech and language processing with deep learning for dementia diagnosis: A systematic review. *Psychiatry Res* **329**, 115538.

[43] Cunningham CT, Quan H, Hemmelgarn B, Noseworthy T, Beck CA, Dixon E, Samuel S, Ghali WA, Sykes LL, Jetté N (2015) Exploring physician specialist response rates to web-based surveys. *BMC Med Res Methodol* **15**, 32.

[44] Shanafelt TD, West CP, Sinsky C, Trockel M, Tutty M, Satele DV, Carlasare LE, Dyrbye LN (2019) Changes in burnout and satisfaction with work-life integration in physicians and the general US working population between 2011 and 2017. *Mayo Clin Proc* **94**, 1681-1694.

[45] Weaver L, Beebe TJ, Rockwood T (2019) The impact of survey mode on the response rate in a survey of the factors that influence Minnesota physicians' disclosure practices. *BMC Med Res Methodol* **19**, 73.

[46] Booker QS, Austin JD, Balasubramanian BA (2021) Survey strategies to increase participant response rates in primary care research studies. *Fam Pract* **38**, 699-702.

[47] Sin J, Munteanu C (2020) An empirically grounded sociotechnical perspective on designing virtual agents for older adults. *Hum Comput Interact* **35**, 481-510.